Background: Thiopurine methyltransferase (TPMT) enzyme activity is measured before initiating thiopurine therapy to reduce the risk of severe drug-associated myelotoxicity in patients with low enzyme activity. TPMT activity may vary over time in relation to drug treatment and patient clinical condition. What constitutes a significant change in TPMT activity can be derived from biological variation and analytical imprecision.
Methods: A large national laboratory database was used to identify patients with three or more TPMT activity measurements. Variance of TPMT activity was analysed by determining the total coefficient of variation (CVTOT) of repeated measurements and by correlation with parameters including gender and follow-up time. Between-run analytical imprecision (CVa) was determined by replicate analysis (n = 314).
Results: Of 7383 patients with TPMT measurements, 136 were identified as having three or more measurements over time (range 3-14). Median CVTOT for individual patient results was 14.5% (range 2.5-36.7%). Analytical imprecision (CVa) was 10.3%. A reference change value (or critical difference) with 95% probability was calculated as 42%. Therefore, a change in measured TPMT activity above 42% should lead to considering sources of variation other than biological variation and analytical imprecision.
Conclusions: TPMT enzyme activity needs to change by at least 42% to determine that a true change has taken place beyond biological variation and analytical imprecision. A single measurement of TPMT activity is sufficient for most clinical purposes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0004563212473441 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Rapid and Reliable Absorbance Assay to Identify Drug-Drug Interactions with Thiopurine Drugs.
Metabolites
December 2024
Department of Medicinal Chemistry, University of Washington, Seattle, WA 98195, USA.
Background: Thiopurine methyltransferase (TPMT) plays a crucial role in the detoxification of thiopurine drugs, including the antimetabolites azathioprine and 6-mercaptopurine (6-MP) used to treat autoimmune diseases and various cancers. These drugs interfere with DNA synthesis by inhibiting the production of purine-containing nucleotides, leading to the death of rapidly dividing cells. TPMT inactivates thiopurine drugs by methylating at the thiol group.
View Article and Find Full Text PDFEfficacy and safety of azathioprine in patients with Cronkhite-Canada syndrome: a case series from Peking Union Medical College Hospital.
BMC Pharmacol Toxicol
December 2024
Department of Gastroenterology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing, 100730, China.
Background: Cronkhite-Canada syndrome (CCS) is a rare non-hereditary chronic inflammatory disease characteristic of gastrointestinal polyps and ectodermal abnormalities. Corticosteroid therapy is the mainstay medication for CCS. Few studies indicated immunosuppressants might be the choices for patients with steroid refractory, steroid dependent or intolerant.
View Article and Find Full Text PDFUtilization and associated factors of TPMT testing among Australian adults receiving thiopurines: A national retrospective data-linkage study.
Pharmacotherapy
January 2025
The University of Sydney School of Pharmacy, Camperdown, New South Wales, Australia.
Introduction: Thiopurine drugs are metabolized by thiopurine methyltransferase (TPMT) and low TPMT activity can result in severe adverse drug reactions. Therefore, TPMT testing is recommended for individuals receiving thiopurines to reduce the risk of toxicity.
Objectives: The objectives of this study were to assess the rate of TPMT testing among individuals receiving thiopurines and explore factors associated with undergoing TPMT testing in Australia.
Contemporary and prospective use of azathioprine (AZA) in viral, rheumatic, and dermatological disorders: a review of pharmacogenomic and nanotechnology applications.
Naunyn Schmiedebergs Arch Pharmacol
November 2024
Department of Pharmacy Practice, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research Pimpri, Pune, Maharashtra, India.
Article Synopsis
- Azathioprine (AZA), commonly used for autoimmune disorders and organ transplants, shows potential for modern applications in viral, rheumatic, and skin diseases.
- Advances in pharmacogenomics and nanotechnology may enhance AZA's effectiveness while reducing side effects, particularly by utilizing the active metabolites 6-mercaptopurine and 6-thioguanine.
- The study suggests that personalized medicine approaches, including genetic testing and innovative drug delivery systems, can improve treatment outcomes for conditions like systemic lupus erythematosus and psoriasis.
Genetic profiling of in the Slovenian population.
Pharmacogenomics
November 2024
University of Ljubljana, Faculty of Pharmacy, Aškerčeva 7, Ljubljana, 1000, Slovenia.
Article Synopsis
- This text discusses the use of pharmacogenomics to tailor thiopurine therapy based on genetic variants, initially focusing on its success in Asian populations but now recognized in European populations as well.
- Researchers sequenced specific gene regions in Slovenian individuals to evaluate the pharmacogenetic role of variants related to thiopurine therapy for patients with acute lymphoblastic leukemia (ALL).
- The study found several genetic variants, including one with known clinical relevance, but most variants were not linked to the dosage of thiopurines in ALL patients, suggesting the need for deeper studies in larger groups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!